Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Sep. 26, 2000

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

Sep. 26, 2000

Biomira reports update of drug development programs

Sep. 25, 2000

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Sep. 21, 2000

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Cel-Sci receives grant for cervical cancer study with Multikine

Sep. 20, 2000

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

Sep. 15, 2000

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Sep. 15, 2000

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

StressGen commences phase II trial of HspE7 for treatment of cervical cancer

Sep. 12, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...